Palvella Therapeutics (PVLA) Assets Average (2014 - 2026)
Palvella Therapeutics (PVLA) reported Assets Average of $161.7 million for Q1 2026, up 92.83% year-over-year from $83.8 million in Q1 2025, and up 155.6% on a QoQ basis from $63.2 million in Q4 2025.
Palvella Therapeutics (PVLA) has 13 years of Assets Average data on file, last reported at $161.7 million in Q1 2026.
- Quarterly Assets Average rose 92.83% year-over-year to $161.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $161.7 million (up 92.83% YoY) and the FY2025 annual result came in at $73.9 million, up 54.3% from the prior year.
- Assets Average rose to $161.7 million in Q1 2026 per PVLA's latest filing, from $63.2 million in the prior quarter.
- Across five years, Assets Average topped out at $161.7 million in Q1 2026 and bottomed at $18.5 million in Q1 2024.
- The 5-year median for Assets Average is $76.6 million (2025), against an average of $78.5 million.
- The widest annual swing landed in 2024, when Assets Average tumbled 79.16%; it then soared 352.62% in 2025.
- Tracing PVLA's Assets Average over 5 years: stood at $97.3 million in 2022, then tumbled by 65.62% to $33.5 million in 2023, then jumped by 62.51% to $54.4 million in 2024, then grew by 16.31% to $63.2 million in 2025, then surged by 155.6% to $161.7 million in 2026.
- Per Business Quant, the three latest PVLA Assets Average figures stand at $161.7 million (Q1 2026), $63.2 million (Q4 2025), and $70.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 161.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 161.66 Mn |
| Dec 31, 2025 | 63.25 Mn |
| Sep 30, 2025 | 70.34 Mn |
| Jun 30, 2025 | 76.59 Mn |
| Mar 31, 2025 | 83.84 Mn |
| Dec 31, 2024 | 54.38 Mn |
| Sep 30, 2024 | 22.79 Mn |
| Jun 30, 2024 | 27.27 Mn |
| Mar 31, 2024 | 18.52 Mn |
| Dec 31, 2023 | 33.46 Mn |
| Sep 30, 2023 | 73.46 Mn |
| Jun 30, 2023 | 84.90 Mn |
| Mar 31, 2023 | 88.87 Mn |
| Dec 31, 2022 | 97.33 Mn |
| Sep 30, 2022 | 106.74 Mn |
| Jun 30, 2022 | 125.71 Mn |
| Mar 31, 2022 | 145.34 Mn |
| Dec 31, 2021 | 158.87 Mn |
| Sep 30, 2021 | 159.61 Mn |
| Jun 30, 2021 | 135.41 Mn |
| Mar 31, 2021 | 110.40 Mn |
| Dec 31, 2020 | 110.37 Mn |
| Sep 30, 2020 | 116.75 Mn |
| Jun 30, 2020 | 120.78 Mn |
| Mar 31, 2020 | 132.44 Mn |
| Dec 31, 2019 | 128.92 Mn |
| Sep 30, 2019 | 123.80 Mn |
| Jun 30, 2019 | 130.94 Mn |
| Mar 31, 2019 | 136.19 Mn |
| Dec 31, 2018 | 146.50 Mn |
| Sep 30, 2018 | 156.84 Mn |
| Jun 30, 2018 | 167.63 Mn |
| Mar 31, 2018 | 138.56 Mn |
| Dec 31, 2017 | 101.37 Mn |
| Sep 30, 2017 | 102.41 Mn |
| Jun 30, 2017 | 83.92 Mn |
| Mar 31, 2017 | 48.47 Mn |
| Dec 31, 2016 | 39.39 Mn |
| Sep 30, 2016 | 45.08 Mn |
| Jun 30, 2016 | 41.83 Mn |
| Mar 31, 2016 | 35.58 Mn |
| Dec 31, 2015 | 35.08 Mn |
| Sep 30, 2015 | 25.34 Mn |
| Jun 30, 2015 | 15.63 Mn |
| Mar 31, 2015 | 19.32 Mn |
| Dec 31, 2014 | 10.93 Mn |
| Sep 30, 2014 | 5,679.00 |
| Jun 30, 2014 | 5,667.00 |
| Mar 31, 2014 | 3.64 Mn |